Search research articles
Contact Us
Filters
Showing results (151-160 of 171) with videos related to
Page
of 18
Sort By:
Nature Cancer
|
April 29, 2025
An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma
Weiqiang Jing, Maosen Han, Ganyu Wang, et al.
Cancer Medicine
|
April 6, 2023
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study
Sujun Han, Zhigang Ji, Junhui Jiang, et al.
Molecular Cancer
|
April 29, 2024
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance
Jianfeng Cui, Xiaochen Liu, Qinghong Shang, et al.
Med (New York, N.Y.)
|
October 17, 2024
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial
Xiaojie Bian, Weijie Gu, Xuepei Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 21, 2023
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
Xinan Sheng, Lin Wang, Zhisong He, et al.
Cell Reports. Medicine
|
April 7, 2026
Patient-derived kidney organoids recapitulate ADPKD and facilitate the identification of Rho pathway inhibitors as candidate therapeutics
Liqiang Guo, Yujia Fan, Huixian Sun, et al.
Journal of the National Cancer Center
|
July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
Huizi Lei, Yun Ling, Pei Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2021
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Xinan Sheng, Haige Chen, Bin Hu, et al.
Signal Transduction and Targeted Therapy
|
April 12, 2026
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial
Junlong Wu, Xinghai Li, Chengyuan Gu, et al.
European Urology
|
July 10, 2026
Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION)
Bi-Ming He, Keqin Zhang, Zhien Zhou, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 171) with videos related to
Sort By:
Page
of 18
Nature Cancer
|
April 29, 2025
An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma
Weiqiang Jing, Maosen Han, Ganyu Wang, et al.
Cancer Medicine
|
April 6, 2023
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study
Sujun Han, Zhigang Ji, Junhui Jiang, et al.
Molecular Cancer
|
April 29, 2024
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance
Jianfeng Cui, Xiaochen Liu, Qinghong Shang, et al.
Med (New York, N.Y.)
|
October 17, 2024
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial
Xiaojie Bian, Weijie Gu, Xuepei Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 21, 2023
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
Xinan Sheng, Lin Wang, Zhisong He, et al.
Cell Reports. Medicine
|
April 7, 2026
Patient-derived kidney organoids recapitulate ADPKD and facilitate the identification of Rho pathway inhibitors as candidate therapeutics
Liqiang Guo, Yujia Fan, Huixian Sun, et al.
Journal of the National Cancer Center
|
July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
Huizi Lei, Yun Ling, Pei Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2021
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Xinan Sheng, Haige Chen, Bin Hu, et al.
Signal Transduction and Targeted Therapy
|
April 12, 2026
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial
Junlong Wu, Xinghai Li, Chengyuan Gu, et al.
European Urology
|
July 10, 2026
Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION)
Bi-Ming He, Keqin Zhang, Zhien Zhou, et al.
Page
of 18